We are live on ! Find out more
DRUG icon

Bright Minds Biosciences
DRUG

11 hedge funds and large institutions have $628K invested in Bright Minds Biosciences in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

22% more funds holding

Funds holding: 9 → 11 (+2)

4.21% less ownership

Funds ownership: 7.7% → 3.5% (-4.2%)

83% less capital inflows, than outflows

Capital inflows: $367K | Capital outflows: $2.13M

Holders
11
Holders Change
+2
Holders Change %
+22.22%
% of All Funds
0.17%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
4
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AdvisorShares Investments
AdvisorShares Investments
Maryland
+$248K
2
Jane Street
Jane Street
New York
+$55.4K
3
Virtu Financial
Virtu Financial
New York
+$32.7K
4
Ikarian Capital
Ikarian Capital
Texas
+$13.4K
5
BlackRock
BlackRock
New York
+$12.6K

Top Sellers

Rank Fund Capital Flow
1
OrbiMed
OrbiMed
New York
-$2.13M

DRUG Hedge Fund Activity: Q1 2022 in Review

11 of the 6,364 institutional investors tracked by Wall St. Rank reported a position in Bright Minds Biosciences (DRUG) for Q1 2022, worth a combined $628K — down 79% from $2.93M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new DRUG positions and 1 closed out — a net gain of 2 holders — while 4 added to existing stakes and 0 trimmed.

The largest buyer was AdvisorShares Investments, adding an estimated $248K. The largest seller was OrbiMed, exiting entirely with an estimated $2.13M sold.

  • 11 institutional investors held Bright Minds Biosciences (DRUG) as of Q1 2022, up from 9 in Q4 2021.
  • Funds reported $628K of Bright Minds Biosciences stock for Q1 2022, down 79% quarter-over-quarter.
  • 3 funds opened new Bright Minds Biosciences positions in Q1 2022 and 1 closed out, a net change of +2 holders.
  • The largest Bright Minds Biosciences buyer in Q1 2022 was AdvisorShares Investments, an estimated $248K added.
  • The largest Bright Minds Biosciences seller in Q1 2022 was OrbiMed, an estimated $2.13M sold.

Based on aggregated 13F filings for Q1 2022.